Novotech Global

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that partners with biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. Founded in 1997, the company has established a significant global footprint, with over 30 offices across the Asia-Pacific region, North America, and Europe, and partnerships with more than 5,000 trial sites. This extensive network provides clients with an accelerated path to bring life-changing therapies to market by offering access to key clinical trial destinations and diverse patient populations. Novotech is committed to a client-centric service model, which seamlessly integrates people, processes, and technologies to deliver customized solutions that expedite market access for new treatments.

The company's expertise spans a wide range of therapeutic areas, including oncology, infectious diseases, vaccines, cell and gene therapies, and rare diseases. Novotech offers a comprehensive suite of services that cover the entire clinical trial lifecycle, from regulatory and drug development consulting to clinical monitoring, data management, and statistical analysis. Their services also include protocol design, feasibility assessments, ethics committee and regulatory submissions, and pharmacovigilance. Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years. With a dedicated team of over 3,000 professionals worldwide, Novotech positions itself as a trusted end-to-end strategic partner, focused on transforming scientific advancements into therapies that improve global health outcomes through a combination of deep therapeutic and regulatory expertise, local market insights, and a commitment to innovation.